In silico molecular modeling of cold pressed garden cress (Lepidium sativum L.) seed oil toward the binding pocket of antimicrobial resistance Staphylococcus aureus DNA-gyrase complexes.

OBJECTIVE: The seeds of garden cress, Lepidium sativum L., are a fantastic source of phytochemicals and proteins. The purpose of the current study was to use solvent extraction techniques to examine the physicochemical characteristics and biological activities of garden cress (L. sativum) seed oil extracts and compounds against Staphylococcus aureus, in vitro, molecular docking and pharmacokinetics. MATERIALS AND METHODS: Cress seed oil were collected from Sakaka, Saudi Arabia's Al-Jouf market. Seeds were crushed in 80% ethanol for several extraction. The oil extraction was forced through a perforated tube, and the meal was expelled via a calibrated aperture. After that, a centrifuge was used to separate the oil from the plant debris (15 min). Study the anti- Staphylococcus aureus of cress seed oil by Well-Diffusion Assay, while cress oil molecules docked against Staphylococcus aureus target (pdb-id: 2XCS) by MOE 19.0901 Software. The pharmacokinetics (ADMET) and Lipinski's rules were predicted by pKCSM online server (available at: https://biosig.lab.uq.edu.au/pkcsm/prediction). RESULTS: The outcome showed that the oil yield for seed oil extract, the specific gravity (0.93) and concentration (33%) was substantially greater. Our findings included a maximal zone of inhibition (23 mm), a minimum inhibitory concentration (MIC) of 80 µg/mL, and a minimum bactericidal concentration (MBC) of 170 µg/mL of cress oil against Staphylococcus aureus. The docking results indicated that the affinity score of Quercetin-3-O-glucosylgalactoside docked against pdb-id: 2XCS was 9.48, while RMSD 1.59 Å compared with the co-crystallized ligand showed an affinity score of -7.58 kcal/mol and RMSD 1.32 Å. CONCLUSIONS: Our findings suggest that Cress seed oil might be utilised to protect food from S. aureus infection that is resistant to antibiotics.

Rapid identification of Streptococcus pneumoniae in blood cultures by using the ImmuLex, Slidex and Wellcogen latex agglutination tests and the BinaxNOW antigen test.

Rapid identification of Streptococcus pneumoniae in blood culture (BC) bottles is important for early directed antimicrobial therapy in pneumococcal bacteraemia. We evaluated a new latex agglutination (LA) test on BC bottles, the ImmuLex™ S. pneumoniae Omni (Statens Serum Institut, Denmark), and compared the performance with the Slidex® pneumo-Kit (bioMérieux, France) and the Wellcogen™ S. pneumoniae (Remel, UK) LA tests, as well as the BinaxNOW® S. pneumoniae (Alere, USA) antigen test. The four tests were directly applied on 358 positive BC bottles with Gram-positive cocci in pairs or chains and on 15 negative bottles. Valid test results were recorded in all cases for ImmuLex and BinaxNOW and in 88.5 % (330/373) and 94.1 % (351/373) of cases for Slidex and Wellcogen, respectively. Based on bottles positive for S. pneumoniae by conventional methods, the sensitivity of ImmuLex was 99.6 %, similar to the other tests (range, 99.6-100 %). Based on bottles positive for non-pneumococcal pathogens, the specificity of ImmuLex was 82.6 %, in comparison to 97.6 % for Slidex (p < 0.01) and 85.4 % for Wellcogen (p = ns). The BinaxNOW test had a lower specificity (64.1 %) than any LA test (p < 0.01). On BC bottles positive for α-haemolytic streptococci, ImmuLex was positive in 12/67 (17.9 %) cases, Slidex in 2/59 (3.4 %) cases, Wellcogen in 11/64 (17.2 %) cases and BinaxNOW in 25/67 (37.3 %) cases. In conclusion, the ImmuLex test provides a valid and sensitive technique for the rapid detection of S. pneumoniae in BC bottles, similar to the other compared methods. However, the specificity was sub-optimal, since the test may cross-react with other Gram-positive bacteria.